Equities Analysts Offer Predictions for JBIO FY2025 Earnings

Jade Biosciences, Inc. (NASDAQ:JBIO) – Analysts at HC Wainwright issued their FY2025 earnings per share estimates for shares of Jade Biosciences in a research note issued to investors on Wednesday, January 7th. HC Wainwright analyst A. He forecasts that the company will post earnings per share of ($2.74) for the year. HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. HC Wainwright also issued estimates for Jade Biosciences’ Q4 2025 earnings at ($0.39) EPS, Q1 2026 earnings at ($0.41) EPS, Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at ($0.44) EPS, Q4 2026 earnings at ($0.46) EPS, FY2026 earnings at ($1.74) EPS and FY2027 earnings at ($2.05) EPS.

Several other brokerages also recently weighed in on JBIO. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jade Biosciences in a report on Monday, December 29th. Guggenheim lifted their price objective on Jade Biosciences from $14.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. BTIG Research assumed coverage on Jade Biosciences in a research report on Thursday, October 9th. They set a “buy” rating and a $28.00 target price on the stock. Finally, Wall Street Zen raised Jade Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.80.

Jade Biosciences Stock Performance

Shares of JBIO opened at $13.25 on Friday. The company has a market capitalization of $653.36 million, a price-to-earnings ratio of -1.19 and a beta of 1.02. The company’s 50 day simple moving average is $13.08 and its 200 day simple moving average is $10.16. Jade Biosciences has a 1 year low of $6.57 and a 1 year high of $100.10.

Jade Biosciences (NASDAQ:JBIO) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.09.

Institutional Investors Weigh In On Jade Biosciences

Institutional investors have recently added to or reduced their stakes in the company. Deltec Asset Management LLC purchased a new position in shares of Jade Biosciences in the 2nd quarter worth about $157,000. Geode Capital Management LLC acquired a new stake in Jade Biosciences during the 2nd quarter worth approximately $6,759,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Jade Biosciences during the 2nd quarter worth approximately $71,000. Intech Investment Management LLC purchased a new position in Jade Biosciences in the second quarter valued at approximately $230,000. Finally, Versant Venture Management LLC acquired a new position in Jade Biosciences during the second quarter valued at approximately $15,243,000.

Key Headlines Impacting Jade Biosciences

Here are the key news stories impacting Jade Biosciences this week:

• Positive Sentiment: HC Wainwright initiated coverage with a “Buy” rating and a $25 price target (about an 88.7% upside from the recent price), giving the stock a favorable analyst catalyst that can drive buying interest. HC Wainwright initiation coverage (MSN)
• Neutral Sentiment: HC Wainwright published a suite of forward EPS estimates by quarter and year (Q4 2025: -$0.39; FY2025: -$2.74; Q1 2026: -$0.41; Q2 2026: -$0.42; Q3 2026: -$0.44; Q4 2026: -$0.46; FY2026: -$1.74; FY2027: -$2.05). These projections underpin the $25 target but reflect ongoing losses — useful for modeling but not an earnings turnaround signal on its own. MarketBeat coverage and analyst estimates
• Negative Sentiment: Despite the bullish initiation, the analyst model still forecasts sustained negative EPS through FY2027, highlighting continued clinical/operational and financing risk; investors should weigh the Buy call against the company’s path to profitability and potential dilution. The Fly: coverage summary

About Jade Biosciences

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.